Key Developments: Harbin Pharmaceutical Group Co Ltd (600664.SS)

600664.SS on Shanghai Stock Exchange

6.28CNY
11 Jul 2014
Price Change (% chg)

¥-0.03 (-0.48%)
Prev Close
¥6.31
Open
¥6.29
Day's High
¥6.34
Day's Low
¥6.26
Volume
6,684,525
Avg. Vol
10,062,710
52-wk High
¥7.04
52-wk Low
¥5.57

Search Stocks

Latest Key Developments (Source: Significant Developments)

Harbin Pharmaceutical Group announces FY 2013 dividend payment
Tuesday, 29 Apr 2014 08:00pm EDT 

Harbin Pharmaceutical Group Co Ltd:To pay cash dividend of 0.66 yuan per 10 shares (before tax) to shareholders for fiscal year 2013.  Full Article

Harbin Pharmaceutical Group Co Ltd announces FY 2013 net profit outlook
Wednesday, 22 Jan 2014 07:00pm EST 

Harbin Pharmaceutical Group Co Ltd:Sees net profit for fiscal year (FY) 2013 to decrease by 60 pct to 70 pct, compared to the net profit of FY 2012 (499,650,000 yuan).Says decrease in revenue from main products due to sales structure change is the main reason for the forecast.  Full Article

Harbin Pharmaceutical Group Co Ltd Announces No Dividend Payment for FY 2012
Friday, 26 Apr 2013 08:00pm EDT 

Harbin Pharmaceutical Group Co., Ltd. announced that it will pay no dividend to shareholders for fiscal year 2012.  Full Article

Harbin Pharmaceutical Group Co Ltd Applies for RMB 23.7 Billion Comprehensive Credit Lines
Friday, 26 Apr 2013 08:00pm EDT 

Harbin Pharmaceutical Group Co Ltd announced that it has decided to apply for a total of RMB 23.7 billion comprehensive credit lines, to 11 branches of 10 banks, for one year, for fiscal year 2013.  Full Article

Harbin Pharm Group Sanjing Pharmaceutical Co Ltd Announces Capital Injection into Subsidiary of Harbin Pharmaceutical Group Co., Ltd.
Wednesday, 17 Apr 2013 08:00pm EDT 

Harbin Pharm Group Sanjing Pharmaceutical Co Ltd (Sanjing Pharm) announced that Sanjing Pharm has signed a capital injection agreement with Harbin Pharmaceutical Group Co., Ltd. (Group A), which holds a 74.82% stake in Sanjing Pharm, and a Harbin-based group (Group B), which hold a 45.06% stake in Group A, on April 17, 2013. According to the agreement, Sanjing Pharm and Group B will inject capital into Group A's wholly owned subsidiary, a Harbin-based pharmaceutical trading company (Company A), to increase Company A's registered capital from RMB 0.5 million to RMB 18 million. After the injection, the three investors will respectively hold a 49% (Sanjing Pharm), a 50% (Group A) and a 1% (Group B) stake in the target company.  Full Article

Search Stocks